๐ ็ธฝ็ฎ้ ๏ฝ ๐ ่ฑๆๅๆ๏ผๆฌ็ฏ๏ผ ๏ฝ ๐ ๅฎๆด็ฟป่ญฏ ๏ฝ โญ ็ฒพ่ฏ็ญ่จ
Cancer
Cancer
INTRODUCTION
Nonmelanoma skin cancer (NMSC) is the most common malignancy in the United States, with over 3 million cases annually.1 NMSC is more common than all other malignancies combined, and its incidence continues to increase.2 This burden has translated into a significant year-on-year increase in disease-related spending.3 As the incidence of NMSC continues to rise, there are significant public health, patient safety, and cost implications, making it imperative that clinicians be able to effectively treat NMSC.